08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

BioDiem, Changchun BCHT deal

BioDiem granted Changchun exclusive rights to its live attenuated influenza virus (LIAV) technology for an egg-based production method for pandemic and seasonal influenza vaccines for the private market in China. BioDiem's LAIV technology delivers a...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

BioDiem, Merck deal

BioDiem regained from Merck's Nobilon International B.V. unit worldwide rights, excluding Russia and the Commonwealth of Independent States (CIS), to BioDiem's live attenuated influenza vaccine (LAIV) technology. BioDiem said Merck returned rights as a result...
07:00 , Oct 18, 2010 |  BC Week In Review  |  Company News

BioDiem, Merck infectious news

Merck informed BioDiem that due to ongoing restructuring efforts following its merger with Schering-Plough Corp. , Merck would be closing its Boxmeer, the Netherlands, facility belonging to the pharma's Nobilon International B.V. unit. The facility...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Financial News

BioDiem completes private placement of common stock and warrants

BioDiem Ltd. (ASX:BDM), Melbourne, Australia   Business: Infectious, Ophthalmic   Date completed: 9/21/10   Type: Private placement of common stock and warrants   Raised: A$1 million (US$946,000)   Shares: 5.6 million   Price: A$0.18  ...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Clinical News

BDM-E regulatory update

FDA granted Orphan Drug designation to BioDiem's BDM-E to treat retinitis pigmentosa. The synthetic peptide is in preclinical testing for the indication. The company is seeking partners and funding to start Phase I testing. BioDiem...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Company News

BioDiem, Serum Institute of India sales and marketing update

Serum Institute launched BioDiem's NasoVac live attenuated influenza vaccine (LAIV) against swine influenza A (H1N1) in India. Serum Institute has a sublicense to the vaccine under the World Health Organization's Pandemic Flu program. Nobilon International...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Financial News

BioDiem completes rights offering

BioDiem Ltd. (ASX:BDM), Melbourne, Australia   Business: Infectious, Ophthalmic   Date completed: 6/25/10   Type: Rights offering   Raised: A$3.5 million (US$3.1 million)   Shares: 19.5 million   Price: A$0.18   Shares after offering: 94.4...
07:00 , Apr 5, 2010 |  BC Week In Review  |  Financial News

BioDiem proposes rights offering

BioDiem Ltd. (ASX:BDM), Melbourne, Australia   Business: Infectious   Date announced: 3/25/10   Type: Rights offering   To be raised: Up to A$7.5 million ($6.9 million)   Shares: 41.9 million   Price: A$0.18   Shares...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Company News

BioDiem, Merck sales and marketing update

BioDiem regained from Merck's Nobilon International B.V. unit full Japanese rights to market BioDiem's live attenuated influenza vaccine (LAIV) technology. The companies previously shared marketing rights to the technology in Japan under a 2004 deal....
07:00 , Oct 19, 2009 |  BC Week In Review  |  Clinical News

SCH 900795: Phase Ib started

Schering-Plough began a double-blind, placebo-controlled, Belgian Phase Ib trial to evaluate intranasal SCH 900795 in 140 healthy adults ages 50 and up. BioDiem granted rights for its LAIV technology to Schering-Plough's Nobilon International B.V. subsidiary...